Domain Therapeutics grants Prexton Therapeutics an exclusive option to license and develop mGluR4 PAMs for Parkinson’s disease
This agreement between Domain Therapeutics and Prexton Therapeutics - a spin-off company of Merck Serono formed around its R&D portfolio in the field of Parkinson’s disease - follows a strategic decision from Merck Serono to focus its research efforts on certain diseases such as multiple sclerosis, cancer and immune-mediated diseases.
Under the terms of the agreement signed between Domain and Prexton, Prexton will benefit from an exclusive license option to progress the mGluR4 PAM drug candidates into clinical development.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.